CD109 Antikörper

Produktnummer ABIN7865575

Der Maus Monoklonal anti-CD109 Antikörper (Klon EBS-CD-046) (ABIN7865575) detektiert spezifisch CD109 in IHC, ICC, FACS und IF. Dieser Antikörper reagiert spezifisch mit Proben aus Human und Affe.

Kurzübersicht für CD109 Antikörper (ABIN7865575)

Target: CD109

Reaktivität: Human, Affe

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD109 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS), Immunofluorescence (IF)

Klon: EBS-CD-046

Produktdetails anti-CD109 Antikörper

Verwendungszweck: anti-CD109 mouse monoclonal, EBS-CD-046, purified

Aufreinigung: affinity chromatography

Immunogen: recombinant human CD109

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise:

ICC/IF_dilution: 1:100-1:200 (0.5-1.0 μg/mL)

FACS_dilution: 0.5-1.0 μg/million cells in 0.1 ml

IHC-frozen_dilution: 1:50-1:100 (1-2 μg/mL)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 100 μg/mL

Buffer: PBS with 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: store at 2 - 8 °C

Details zu CD109

Target: CD109

Andere Bezeichnung: CD109

Hintergrund: CD109 is a GPI-anchored member of the alpha-2-macroglobulin (A2M) and complement family of proteins. It is expressed on activated T-cells, platelets, hematopoietic stem cells, megakaryocyte precursors, vascular endothelial cells, basal and myoepithelial cells of secretory glands, and squamous cell carcinomas. A 170-180 kDa precursor is autocatalytically reduced to 150 kDa and 120 kDa forms. On keratinocytes CD109 binds TGF-beta and associates with TGF-beta RI and TGF-beta RII, resulting in inhibition of TGF-beta signalling. Polymorphisms of CD109 include the platelet-specific Gov antigen and the blood group ABH antigens. Alloantibodies directed against these antigens result in unsuccessful platelet transfusions, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. Positive control: Human platelets, blood vessels.

Pathways: Activated T Cell Proliferation